Viking Therapeutics Advised to Hedge Against Market Risks Amidst Regulatory Delays
PILLAR DIAGNOSTIC // WEEK 05
“A binding regulatory bottleneck is colliding with bullish Phase 3 enrollment expectations, while the market has yet to fully price the extended timeline risk, making strength vulnerable to a pullback.”
Proposed action
Hedge or trim long exposure and avoid initiating new positions
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
VK2735 achieved 14.7% weight loss in Phase 2 and has progressed into two global Phase 3 VANQUISH studies—VANQUISH-1 with about 4,650 patients enrolled and VANQUISH-2 enrollment on track for late 2026—while a strong cash position is expected to fund VK2735 through Phase 3 and support future pipeline work.
THE MAP
Structure & constraints
Absence of a marketed obesity therapy ensures zero near-term revenue and underscores a regulatory bottleneck, even as challengers develop dual GIP/GLP-1 and amylin/calcitonin receptor agonists against entrenched pharma giants.
THE MOOD
Consensus & positioning
Investor optimism around VK2735’s clinical milestones and blockbuster potential is balanced by deep concerns over multi-year unprofitability, mixed mid-stage data, intensifying competition, and an extended regulatory timeline, leaving sentiment cautiously upbeat but wary.